Erlotero (Erlotinib Tablet) 100 mg

Erlotero (Erlotinib) 100 mg tablets are used for cancer treatment support. This oral therapy helps manage certain types of tumors by targeting specific pathways. Suitable for ambient storage, it offers a 30-tablet pack size for prescribed regimens.

Strength

100 mg

Pack Size

30s

Storage

Ambient

Manufacturer / TM Owner

Hetero Healtchare Ltd

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Erlotero (Erlotinib) 100 mg tablets are prescribed to support treatment for non-small cell lung cancer and pancreatic cancer when used as directed by a healthcare professional. It belongs to a class of medications that work by slowing or stopping the growth of cancer cells. Patients often ask, 'what is Erlotinib 100 mg used for' in managing advanced cancer cases.

Side Effects

Erlotero (Erlotinib) 100 mg tablets may cause mild to moderate side effects such as nausea, rash, or diarrhea. Some users report fatigue or loss of appetite during therapy. These effects vary by individual and should be monitored by a healthcare provider.

Precautions & Warnings

Store Erlotero (Erlotinib) 100 mg tablets at room temperature away from moisture and heat. Keep out of reach of children and pets. Avoid crushing or splitting tablets unless advised by a doctor. Report any unusual symptoms to your healthcare team promptly.

Avoid Interactions

Erlotero (Erlotinib) may interact with certain medications, including strong CYP3A4 inhibitors or inducers, anticoagulants, and gastric acid reducers. Alcohol and grapefruit products may also affect how Erlotinib works. Always inform your doctor about all medications and supplements you are taking.

Frequently Asked Questions

Erlotero (Erlotinib) 100 mg is prescribed to help manage certain types of cancer, including non-small cell lung cancer and pancreatic cancer.

Store at room temperature away from moisture and heat. Keep the medication in its original packaging until ready to use.

Erlotero (Erlotinib) should be taken on an empty stomach at least one hour before or two hours after eating, unless directed otherwise.

Common side effects may include rash, diarrhea, nausea, fatigue, or loss of appetite. Report persistent symptoms to your doctor.

No, Erlotero (Erlotinib) requires a prescription from a licensed healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.